WO2016192669A1 - Procédé et médicament pour la perte de poids et pour la diminution de la glycémie et de la lipidémie par l'intermédiaire de mir-96, et utilisation associée - Google Patents

Procédé et médicament pour la perte de poids et pour la diminution de la glycémie et de la lipidémie par l'intermédiaire de mir-96, et utilisation associée Download PDF

Info

Publication number
WO2016192669A1
WO2016192669A1 PCT/CN2016/084710 CN2016084710W WO2016192669A1 WO 2016192669 A1 WO2016192669 A1 WO 2016192669A1 CN 2016084710 W CN2016084710 W CN 2016084710W WO 2016192669 A1 WO2016192669 A1 WO 2016192669A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
inhibitor
seq
nucleotide sequence
obesity
Prior art date
Application number
PCT/CN2016/084710
Other languages
English (en)
Chinese (zh)
Inventor
彭长庚
温婷
Original Assignee
昆山彭济凯丰生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 昆山彭济凯丰生物科技有限公司 filed Critical 昆山彭济凯丰生物科技有限公司
Publication of WO2016192669A1 publication Critical patent/WO2016192669A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates to the field of biomedicine, and in particular to the prevention and/or treatment of hyperlipemia, fatty liver, obesity, diabetes, and diseases thereof by inhibiting the function of miR-96, a marker of hyperlipemia, fatty liver, obesity or diabetes.
  • Excessive energy intake is the most fundamental cause of hyperlipidemia, fatty liver and obesity, and obesity is recognized as a cause of type 2 diabetes.
  • the brain the hypothalamus is particularly important
  • the central axis of the gastrointestinal tract plays an important regulatory role in appetite, feeding and digestion and absorption, as well as blood glucose concentration and fat metabolism [1], so the gene expression in the hypothalamus-gastrointestinal is very variable. May be the most fundamental cause of obesity.
  • Excessive energy intake will first cause fatty liver, which in turn changes the expression of genes in the liver, causing abnormalities in lipid metabolism and causing cardiovascular disease.
  • brain-gastrointestinal-hepatic central axis plays an important regulatory role in blood glucose metabolism [2], indicating that the brain-gastrointestinal-hepatic central axis may be a new target organ system for the treatment of obesity and diabetes [3].
  • MicroRNAs are a class of non-coding RNA molecules (www.mirbase.org) that are 16-25 nt in length and are capable of recognizing and silencing RNA expression and/or protein expression of a target gene by complementary pairing with a target gene. After the mature microRNA is loaded onto the RNA-induced silencing complex (RISC), it is combined with the complementary sequence in the 3'-UTR of the target gene mRNA by base pairing, thereby triggering the degradation of the mRNA and/or inhibiting its protein. translation. The nucleotides from the second to the eighth position of the 5' end of the microRNA are called "core sequences".
  • RISC RNA-induced silencing complex
  • the complementary pairing of these seven nucleotides with the target gene is the key to recognition of the target gene.
  • Simultaneous pairing of sequences other than the "core sequence" of the microRNA with the target gene also enhances its ability to bind and regulate the target gene. It is precisely because microRNAs recognize and regulate the expression of target genes through incomplete pairing that a microRNA can simultaneously regulate multiple target genes to different degrees in one cell.
  • microRNA-based drugs that control energy metabolism is a trend.
  • the present invention provides a function of inhibiting hyperlipemia, fatty liver, obesity or diabetes, miR-96, in preventing and/or treating hyperlipemia, fatty liver, obesity, diabetes, and diseases thereof.
  • the application of symptoms similar to symptoms.
  • the present invention provides a method of inhibiting the function of a marker miR-96 of hyperlipemia, fatty liver, obesity or diabetes, wherein the method comprises: targeting a miR-96 inhibitor to a target expressing miR-96 Cell contact.
  • the present invention provides a miR-96 inhibitor, wherein the miR-96 inhibitor is an antisense oligonucleotide comprising antisense DNA and antisense RNA, the antisense oligonucleotide Complementary to miR-96 and having a length of 8-23 nucleotides; or the miR-96 inhibitor is a small interfering RNA of the miR-96 precursor.
  • the miR-96 inhibitor is an antisense oligonucleotide comprising antisense DNA and antisense RNA, the antisense oligonucleotide Complementary to miR-96 and having a length of 8-23 nucleotides; or the miR-96 inhibitor is a small interfering RNA of the miR-96 precursor.
  • the present invention also provides a pharmaceutical composition, wherein the pharmaceutical composition comprises a miR-96 inhibitor as described above and a pharmaceutically acceptable carrier.
  • the present invention also provides a kit, wherein the kit comprises a miR-96 inhibitor as described above, optionally, the kit further comprising a pharmaceutically acceptable carrier.
  • the present invention provides a method as described above, a miR-96 inhibitor as described above, a pharmaceutical composition as described above and/or a kit as described above, in inhibiting the function of miR-96 Applications; especially in the prevention and/or treatment of hyperlipidemia, fatty liver, obesity, diabetes, and symptoms similar to those of these diseases.
  • the present invention provides the use of a miR-96 inhibitor as described above, a pharmaceutical composition as described above, for the preparation of a medicament for inhibiting the function of miR-96; in particular for preparation for prevention and / or the use of drugs for the treatment of hyperlipidemia, fatty liver, obesity, diabetes and symptoms similar to those of these diseases.
  • the present invention can fully inhibit the function of miR-96 by contacting a miR-96 inhibitor with a target cell expressing miR-96 (including inhibiting the binding of miR-96 to its target gene or reducing the expression level of miR-96, thereby inhibiting The function of miR-96), when used for individual administration, can effectively prevent and/or treat diseases caused by an increase in the amount of miR-96, for example, hyperlipemia, fatty liver, obesity, diabetes or with these diseases. Symptoms with similar symptoms. Compared with the traditional single hypoglycemic or single hypolipidemic or single weight loss drugs, the present invention provides a comprehensive treatment for appetite, glycolipid metabolism and adipocyte differentiation, and thus has powerful effects and small side effects.
  • Figure 1 shows the expression levels of miR-96 in the hypothalamus, stomach and liver of 12-month-old mice relative to 2 month old mice.
  • Figure 2A is a linear plot of miR-96 ASO dose versus its inhibitory effect on miR-96.
  • Figure 2B is a comparison of the functional effects of miR-96 ASO, randomized control nucleotides, miR-96 mismatched ASO at the cellular level to inhibit miR-96.
  • Figure 3A is a graph comparing the changes in body weight over time in mice injected with miR-96 ASO and PBS, respectively.
  • Figure 3B is a graph comparing the rate of weight gain over time in mice injected with miR-96 ASO and PBS, respectively.
  • Figure 3C is a graph comparing blood glucose concentrations of mice injected with two and a half months of miR-96 ASO and PBS, respectively.
  • Figure 4A is a graph comparing the weight of liver, epididymal fat and stomach of mice injected with miR-96 ASO and PBS for three months, respectively.
  • Figure 4B is a graph comparing the weight of epididymal fat and stomach to body weight of miR-96 ASO and PBS injected for three months, respectively.
  • Figure 4C is a graph comparing the weight to body weight ratio of liver and kidney for miR-96 ASO and PBS injected for three months, respectively.
  • Figure 4D is a graph comparing the levels of total cholesterol, triglyceride, high density lipoprotein and low density lipoprotein in the serum of mice injected with miR-96 ASO and PBS for three months, respectively.
  • Figure 5 is a graph comparing the effect of miR-96 siRNA and random control RNA on miR-96 expression.
  • Figure 6 is a graph showing the comparison of fasting blood glucose in mice administered by oral gavage for 14 weeks of thio-miR-96 ASO, physiological saline, and thio-modified random nucleotides.
  • 7A-C are comparative graphs of mouse body weight growth rate, liver weight, and liver coefficient, respectively, for 14 weeks of oral administration of thio-miR-96 ASO, physiological saline, and thio-modified random nucleotides.
  • Figures 8A-D are cholesterol, triglyceride, high-density lipoprotein, and low-density in the blood of mice administered orally by intragastric administration for 14 weeks of thio-miR-96 ASO, saline, and thio-modified random nucleotides. A comparison of the concentrations of lipoproteins.
  • Figure 9 is a graph showing the effect of oral administration of thio-miR-96 ASO, physiological saline, and thio-modified random nucleotides on the formation of fatty liver in mice by oral gavage for 14 weeks.
  • the inventors of the present invention found in the course of the study that the miR-96 in the hypothalamic-gastric axis of the dominant appetite was significantly up-regulated in the 12-month-old mouse compared to the 2 month old mouse, and The expression in the liver is also significantly upregulated. Based on the above findings, the inventors used the TargetScanHuman (www.targetscan.org) algorithm to predict the target gene of miR-96 that is conserved in vertebrates, and then compared with the KEGG pathway, many target genes of miR-96 are enriched in sugar. , lipids, and signaling pathways regulating glycoprotein metabolism, as well as in the insulin signaling pathway, the diabetic signaling pathway, and the adipocytokine pathway (Table 1).
  • Another 20 miR-96 target genes are located in the MAPK signaling pathway, 9 miR-96 target genes are located in the Wnt signaling pathway and 3 target genes are located in the Hedgehog signaling pathway (Table 1); these three signaling pathways are known to be inhibitory Adipocyte differentiation and proliferation [5].
  • six miR-96 targets were involved in the appetite-adjusting Jak-STAT signaling pathway (Table 1).
  • miR-96 can be used as a marker for hyperlipemia, fatty liver, obesity or diabetes, and subsequently demonstrated that hyperlipemia and fatty liver can be prevented and/or treated by inhibiting the function of miR-96. , obesity, diabetes, and symptoms similar to those of these diseases.
  • the present invention provides the use of the marker miR-96, which inhibits hyperlipemia, fatty liver, obesity or diabetes, for the prevention and/or treatment of the following diseases and/or symptoms: hyperlipemia, fatty liver, obesity, diabetes, and Symptoms similar to the symptoms of these diseases, a miR-96 inhibitor, a method of inhibiting the function of miR-96 by the miR-96 inhibitor, and pharmaceutical compositions and kits including the miR-96 inhibitor, and They are used in the prevention and/or treatment of hyperlipidemia, fatty liver, obesity, diabetes and symptoms similar to those of these diseases.
  • the present invention provides a method of inhibiting the function of the marker miR-96 of hyperlipemia, fatty liver, obesity or diabetes, wherein the method comprises: contacting a miR-96 inhibitor with a target cell expressing miR-96.
  • miR-96 has SEQ ID No: 1 (NUUGGCACUAGCACAUUUUUGCU) The nucleotide sequence shown.
  • the "inhibition of the function of miR-96” refers to the degree of down-regulation of miR-96 expression of its target gene in a target cell expressing miR-96 of the same species which is not treated by the method of the present invention, In the target cells expressing miR-96 treated by the present invention, the degree of down-regulation of miR-96 expression of its target gene by at least 0.5 fold is reduced by at least a factor of 0.5, such as Figures 2A and 2B.
  • the present invention provides a method of inhibiting miR-96 function in a target cell expressing miR-96 in vivo or in vitro.
  • inhibiting the function of miR-96 means that the expression level of a target gene regulated by miR-96 is increased by directly or indirectly acting on miR-96 with an agent. Methods include, but are not limited to, the following:
  • MiR-96 inhibitors include, but are not limited to, naturally occurring or synthetic small molecule compounds that act directly on miR-96 to increase the expression of a target gene regulated by miR-96, usually molecular weight.
  • candidate compounds possess functional groups that interact with proteins, particularly hydrogen bonds, and typically comprise at least one amine, carbonyl, hydroxyl or carboxyl group.
  • the antisense oligonucleotide is capable of inhibiting the function of the target miR-96 by direct binding to the target miR-96, including antisense RNA and antisense DNA.
  • the antisense oligonucleotide is complementary to miR-96, has a length of 8-23 nucleotides, and has a sequence complementary to nucleotides 2-8 of miR-96.
  • microRNAs can recognize and silence the expression and/or translation of a target gene by complementary pairing with a target gene.
  • miR-96 can also bind to a partially complementary core.
  • the nucleotide sequence competitively inhibits its own function, thereby upregulating the expression of the target gene of miR-96.
  • the term "complementary" includes not only complete complementarity but also partial complementarity.
  • the antisense oligonucleotide has the following nucleotide sequence:
  • the antisense oligonucleotide When in the case of incomplete complementation, that is, when the antisense oligonucleotide is deleted, substituted or added by one or several nucleotides in the nucleotide sequence shown in SEQ ID No:
  • the antisense oligonucleotide preferably has at least 60%, 65%, 70% with miR-96 in the region of the complementary nucleotide. 75%, 80%, 85%, 90% or 95% complement each other. More preferably, the antisense oligonucleotide has a mismatch of up to 3 nucleotides in the region of nucleotides 2-8 of miR-96.
  • the antisense oligonucleotide is not completely complementary to miR-96, it is further preferred that there are at most 10, 9 in length compared to SEQ ID No: 4. A difference of 8, 7, 6, 5, 3, 2 or 1 nucleotides.
  • the antisense oligonucleotide that is not fully complementary to miR-96 has the nucleotide sequence set forth in SEQ ID No: 5 (TAGTGAATTCTGCTAGTGCCATA).
  • the present invention also encompasses some conventional modifications of the antisense oligonucleotide to improve the stability and activity of the antisense oligonucleotide, all of which are within the scope of the invention.
  • the stability of antisense oligonucleotides is enhanced by conventional 5'-O-1-thiotriphosphate modifications or locked nucleic acids or 2'-O-methyl modifications.
  • 1-5 bases at both ends of the nucleotide sequence set forth in SEQ ID No: 4 may be modified with a thiotriphosphate.
  • the two phosphate esters at both ends of the nucleotide acid sequence set forth in SEQ ID No: 4 are thiolated (eg, A S G S CAAAAATGTGCTAGTGCCA S A S A).
  • RNA is DNA.
  • the antisense oligonucleotide is capable of being complementary (fully complementary or partially complementary) to miR-96, when the antisense oligonucleotide is contacted with a target cell expressing miR-96 in vivo or in vitro,
  • the antisense oligonucleotide is capable of complementary pairing with miR-96 and inhibits the binding of miR-96 to its target gene (ie, inhibits the activity of miR-96), thereby breaking the silence of miR-96 on its target gene.
  • the method comprises introducing an effective amount of an antisense oligonucleotide complementary to miR-96 into a target cell expressing miR-96.
  • the "effective amount” varies depending on the target cell expressing miR-96, and exhibits a certain dose effect, as shown in FIG. 2A of the present invention, according to conventional experimental means by those skilled in the art. And the intended purpose achieved can readily determine the effective dose for target cells expressing miR-96.
  • the antisense oligonucleotide of the present invention can be administered to an individual by conventional methods of nucleic acid administration.
  • administration of the antisense oligonucleotide can be carried out using the following method: the antisense oligonucleotide can be administered by a method of viral infection, microinjection, or vesicle fusion, or can also be passed A method of jet injection is used for muscle administration of the antisense oligonucleotide.
  • the antisense oligonucleotide may be applied to gold particles and then transdermally administered by a known method such as a particle bombardment apparatus or a "gene gun". These are all technical means conventional in the art, and the present invention will not be repeated here.
  • the antisense oligonucleotide can also be introduced into a target cell expressing miR-96 by an expression vector.
  • expression vectors have a restriction site located adjacent to the promoter sequence to facilitate insertion of the antisense oligonucleotide.
  • the transcription cassette located in the expression vector may include a transcription initiation region, a target gene or a fragment thereof, and a transcription termination region.
  • the vector can be, for example, but not limited to, a plasmid, a virus, etc., and can be selected by a person skilled in the art according to actual conditions.
  • antisense oligonucleotides can also be introduced into target cells expressing miR-96 by means of respiratory spray administration, for example by preparation into a spray formulation.
  • the antisense oligonucleotide may also be introduced into a target cell expressing miR-96 by oral administration, for example, by preparation into an oral preparation, or by the antisense The oligonucleotide is administered orally in a manner that is mixed with the food.
  • An individual as described above may be any mammalian cell, including but not limited to: ungulates, eg, cows, goats, pigs, sheep, etc.; rodents, eg, hamsters, mice, rats, rabbits; primates For example, monkeys, baboons, humans, etc.
  • the antisense oligonucleotide or a vector containing the antisense oligonucleotide can be directly added to The substrate in which the target cell expressing miR-96 is cultured is contacted, and the target cell expressing miR-96 into which the antisense oligonucleotide is introduced is cultured under conventional cell culture conditions.
  • the RNAi agent targets a precursor molecule of miR-96 (pre-microRNA, as shown in SEQ ID No: 2, UGGCCGAUUUUGGCACUAGCACAUUUUUGCUUGUGUCUCUCCGCUCUGAGCAAUCAUGUGCAGUGCCAAUAUGGGAAA), modulating miR-96 by a mechanism of RNA interference
  • pre-microRNA as shown in SEQ ID No: 2, UGGCCGAUUUUGGCACUAGCACAUUUUUGCUUGUGUCUCUCCGCUCUGAGCAAUCAUGUGCAGUGCCAAUAUGGGAAA
  • RNA interference is a phenomenon in which homologous mRNA is efficiently and specifically degraded by double-stranded RNA (dsRNA). Since RNAi technology can specifically knock out or turn off the expression of specific genes, this technology has been widely used to explore the field of gene function and treatment of infectious diseases and malignant tumors.
  • the present application by using interfering RNA of the precursor molecule of miR-96, causes gene silencing of the precursor molecule of miR-96, thereby reducing the level of the precursor molecule of miR-96, thereby reducing The level of mature miR-96 converted from the precursor molecule of miR-96, ie, inhibits miR-96 The function of this increases the expression level of the miR-96 target gene.
  • the RNAi agent can be a small RNA molecule, usually a single-stranded deoxyoligonucleotide (shRNA) that theoretically forms a small hairpin structure, typically no more than 100 nucleotides in length, typically No more than 75 nucleotides; or a 15-30 bp double-stranded deoxyoligonucleotide (siRNA), most typically 20-23 bp, as described in Example 5 of the present invention (eg SEQ)
  • the antisense strand represented by ID No: 7 and the sense strand as shown in SEQ ID No: 8.
  • the RNAi agent can also be a template DNA encoding shRNA or siRNA.
  • template DNA may be present in a vector, such as a plasmid vector or a viral vector; or may be absent from the vector, but a template DNA encoding shRNA or siRNA plus a common promoter sequence fragment that controls its transcription.
  • the contact of the RNAi agent with the target cell expressing miR-96 may also be in vivo contact or in vitro contact.
  • the method of administering the RNAi agent can be carried out with reference to the description of the antisense oligonucleotide as described above, and the present invention will not be described in detail herein in order to avoid unnecessary repetition.
  • the present invention also provides a miR-96 inhibitor, the specific type of which is as described above, and the present invention will not be described in detail herein in order to avoid unnecessary duplication.
  • the present invention also provides a pharmaceutical composition comprising the miR-96 inhibitor as described above and a pharmaceutically acceptable carrier.
  • the content of the miR-96 inhibitor as described above as an active ingredient may vary within a wide range, and may be, for example, 0.01 to 99%, preferably 1 to 70%. More preferably, it may be 5-30%.
  • the pharmaceutical composition can be prepared into various dosage forms conventional in the art, and the present invention is not particularly limited thereto, and for example, it can be formulated into a solid, semi-solid, liquid or gaseous form, for example, a tablet. , capsules, elixirs, suspensions, syrups, powders, granules, ointments, suppositories, injections, inhalants, aerosols, and the like, which are not enumerated herein.
  • various forms of administration may be carried out depending on the pharmaceutical dosage form, such as, but not limited to, oral administration, buccal administration, rectal administration, parenteral administration, intraperitoneal administration, and respiratory administration. , intradermal administration, percutaneous administration medicine.
  • the pharmaceutically acceptable carrier can be selected differently depending on the dosage form, which are well known to those skilled in the art.
  • the pharmaceutically acceptable carrier can be starch, gum, lactose, glucose, sucrose, microcrystalline cellulose, kaolin, mannitol, dibasic calcium phosphate, sodium chloride, alginic acid, and the like.
  • additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives may also be added.
  • the pharmaceutically acceptable carrier may further comprise a targeting agent capable of enhancing targeting of the antisense oligonucleotide to a particular organ or tissue or cell, such as a targeting peptide, and may also These include transmembrane agents that are capable of carrying the antisense oligonucleotides more readily into target cells expressing miR-96, such as transmembrane peptides, liposomes, microvesicles, and membrane lipoproteins.
  • a targeting agent capable of enhancing targeting of the antisense oligonucleotide to a particular organ or tissue or cell, such as a targeting peptide
  • transmembrane agents that are capable of carrying the antisense oligonucleotides more readily into target cells expressing miR-96, such as transmembrane peptides, liposomes, microvesicles, and membrane lipoproteins.
  • a flavoring agent such as peppermint, wintergreen oil or the like may be added to the pharmaceutical composition.
  • coloring agents may also be added to the pharmaceutical composition to impart a certain degree of attractiveness to the prepared dosage form or to distinguish it from other products.
  • the antisense oligonucleotide can also be combined with other conventional drugs capable of similar effects to prepare a combination pharmaceutical composition.
  • it can be combined with insulin to prepare a drug for effective treatment of diabetes.
  • kits wherein the kit comprises an antisense oligonucleotide as described above, optionally, the kit further comprises an additional reagent, for example, pharmaceutically acceptable as described above Accepted carriers, flavoring and/or coloring agents, solubilizing agents, isotonic agents, suspending agents, emulsifying agents, stabilizers, preservatives, targeting agents or transmembrane agents.
  • additional reagent for example, pharmaceutically acceptable as described above Accepted carriers, flavoring and/or coloring agents, solubilizing agents, isotonic agents, suspending agents, emulsifying agents, stabilizers, preservatives, targeting agents or transmembrane agents.
  • the additional reagent may be present in the kit in combination with the antisense oligonucleotide, or may be stored separately in the kit and mixed again when used.
  • the kit of the present invention may further include an instruction manual, and the form of the specification is not particularly limited, and may be, for example, a printed paper form, a CD form, or a web address. Get access to it via the internet.
  • the present invention provides the prevention of the function of miR-96, a marker for inhibiting hyperlipemia, fatty liver, obesity or diabetes. And/or for the treatment of at least one of the following diseases and/or conditions.
  • the diseases and/or symptoms include: hyperlipidemia, fatty liver, obesity, diabetes, and symptoms similar to those of these diseases.
  • the use comprises the preparation of a medicament and/or food for the prevention and/or treatment of any of the above diseases and/or symptoms.
  • the food product comprises a health care product.
  • the invention also provides the use of a miR-96 inhibitor as described above, a pharmaceutical composition as described above, a kit as above and/or a method as described above for inhibiting the function of miR-96.
  • the use comprises preventing and/or treating any of the above diseases and/or symptoms.
  • the present invention provides the use of the miR-96 inhibitor as described above, the pharmaceutical composition as described above, in the preparation of a medicament for reducing the amount of miR-96.
  • the medicament comprises a medicament and/or a food for preventing and/or treating any of the above diseases and/or symptoms.
  • the food product comprises a health care product.
  • the treatment refers to an improvement or complete disappearance of a subject's symptoms associated with a disease or condition caused by miR-96, wherein a broad sense of improvement refers to a reduction of at least one parameter.
  • a broad sense of improvement refers to a reduction of at least one parameter.
  • it may be a reduction in body weight, a decrease in blood fat and/or blood sugar, an improvement in fatty liver, and the like.
  • the individual to be treated can be any individual, preferably a mammal, afflicted with the symptoms described above.
  • the "inhibition of the function of miR-96” refers to the degree of down-regulation of miR-96 expression of its target gene in a target cell expressing miR-96 of the same species which is not treated by the method of the present invention, In the target cells expressing miR-96 treated by the present invention, the degree of down-regulation of miR-96 expression of its target gene by at least 0.5 fold is reduced by at least a factor of 0.5, such as Figures 2A and 2B.
  • the miR-96 gene (GGTACAAAGACCTCCTCTGCTCCTTCCCCAGAGGGCCTGTTCCAGTACCATCTGC TTGGCCGATTTTGGCACTAGCACATTTTGGCTTGTGTCTCTCCGCTGTGAGCAATCAT GTGTAGTGCCAATATGGGAAAAGCGGGCTGCTGC GGCCACGTTCACCTCCCCCGGCATCC ) shown in SEQ ID No: 3 was cloned into the pCAG-GFP vector to obtain the overexpression plasmid pCAG-miR-96-GFP of the miR-96 gene. Among them, the synthesis and cloning of the miR-96 gene shown by SEQ ID No: 3 was carried out by Kingsray.
  • miR-96 sensor vector miR-96 sensor vector
  • the miR-96 receptor vector is a fire luciferase gene 3 cloned into the pGL3-SV40 vector by binding a confirmed miR-96 binding and regulatory target sequence (AAAGAAACCATCAAGTTGTGCCAAA) as shown in SEQ ID No:11. 'The downstream xbaI site was obtained, so that the expression of fire luciferase in the miR-96 receptor vector was regulated by miR-96.
  • This example is used to illustrate the difference in miR-96 expression in 2 month old and 12 month old mice.
  • Adipose tissue Add 1 ml of Trizol reagent (invitrogen) to the blood and mix. Add 200 ⁇ l of Trizol reagent to the hypothalamus, stomach, liver, muscle and adipose tissue, then cut the hypothalamus, stomach, liver, muscle and adipose tissue with scissors, and then grind these tissues into pieces with an electric homogenizer. Then, the total RNA in one tissue was extracted according to the instructions of Trizol.
  • RNA was solubilized with nuclease-free water, and then the ratio of 260 to 280 of the RNA was determined using a Nanodrop 2000 instrument, and samples with a ratio greater than 1.8 were continued for subsequent experiments. After the concentration of RNA was determined by Qubit, the integrity of the RNA was detected using a bioanalyzer, and the RNA integrity index RIN was greater than 0.9. Among them, in order to ensure that each tissue or organ can perform subsequent experiments, multiple replicates can be set for total RNA extraction.
  • RNA 1 ⁇ g of total RNA was taken from each sample, and 10-40 nt of short RNA in total RNA was isolated using a flashPAGE sieving apparatus (Ambion), and then a microRNA cDNA library was prepared by reverse transcription using an Illumina kit, and then in a second The expression level of microRNA in the sample was determined on a generation sequencer.
  • the results showed that the expression of miR-96 in the hypothalamus, stomach and liver of the 12-month-old mice was higher than that in the 2-month-old mice, indicating that the expression level of miR-96 increased with age in the hypothalamus. Increased in the stomach and liver, positively correlated with weight gain and obesity.
  • miR-96 was detected by quantitative PCR. Take [mu] g of total RNA from each sample, miRNA & mRNA RT-PCR kit (Pengekiphen, Kunshan) trans micro RNA and mRNA transcribed cDNA with a Catch All TM.
  • the primers used for detection were: miR-96 forward primer (5'-TTTGGCACTAGCACATTTTTGCT-3') as shown in SEQ ID No: 12; U6 forward primer as shown in SEQ ID No: 13 (5'-CGCAAGGATGACACGCAAATTCG) -3');
  • the reverse primer is a universal primer provided for the kit.
  • the instrument to be tested was Bio-Rad's iQ5 system and the reagent was TaKaRa's SYBR Green Mix. Three replicate wells were simultaneously detected for each sample, and U6 was used as an internal reference to calculate the expression level of miR-96 in each sample by the 2- ⁇ ct method. The expression level of miR-96 in each organ of 2 month old mice was then set to 1, and the relative expression level of miR-96 in 12-month-old mice was calculated. The results are shown in Fig. 1.
  • the expression level of miR-96 in the hypothalamic-gastric central axis of the appetite was significantly up-regulated in 12-month-old mice, and the expression of miR-96 in the liver was also significantly up-regulated.
  • Quantitative PCR confirmed that the expression levels of miR-96 in the hypothalamus, stomach and liver of the 12-month-old mice were 1.5, 1.7 and 2.4 times higher than those in the 2-month-old mice, respectively. It can be shown that the upregulation of miR-96 is associated with obesity and fatty liver formation. Among them, in Fig. 1, **P ⁇ 0.01, *p ⁇ 0.05.
  • This example is to illustrate the in vitro regulation of antisense oligonucleotides on miR-96
  • HEK-293T Human embryonic kidney cells HEK-293T were cultured in DMEM medium containing 10% fetal bovine serum. The cell culture incubator was constantly maintained at 37 ° C and 5% CO 2 . HEK-293T cells were seeded in a 24-well cell culture plate at a seeding rate of 100,000 cells per well at a culture volume of 500 ⁇ l. The following day, the settings of Table 2 below were co-transfected into KEK-293 cells using liposome 2000 (Invitrogen) according to the instructions, and expression from the miR-96 receptor vector was measured 36 hours later using a dual luciferase analyzer (Promega). The luciferase activity. Three replicate wells were set each time and the experiment was repeated three times.
  • the transfer amount of miR-96 receptor vector in each group was 500 ng for miR-96 receptor vector, 20 ng for pCAG-GFP blank vector, 500 ng for miR-96 overexpression vector, and 50 ⁇ M for oligonucleotide.
  • the solution Further, when the transferred oligonucleotide was miR-96 ASO, 0.5 ⁇ l and 1 ⁇ l of a 50 ⁇ M oligonucleotide solution were respectively added, and the final concentrations were 0.0417 ⁇ M and 0.0833 ⁇ M, respectively, after being added to the cell culture solution. To determine the activity of luciferase, and to use it as the ordinate, the concentration of miR-96 ASO is plotted on the abscissa. The results are shown in Figure 2.
  • miR-96 ASO inhibits the function of miR-96.
  • the miR-96 receptor vector, miR-96 overexpression vector and different concentrations of miR-96 ASO were co-transfected, and the luciferase activity assay showed that miR-96 ASO could inhibit the function of miR-96. And there is a dose effect.
  • miR-96 inhibits the expression of miR-96 receptor vector (left 1 column and left 2 column); miR-96 ASO and miR-96 mismatch ASO can inhibit miR-96 function ( Left 3 column and left 5 column), miR-96
  • miR-96 in HEK293 cells inhibited the expression level of the reporter luciferase in the miR-9 receptor vector to 47% of the control level, while co-transforming the final concentration of 0.0833 ⁇ M of miR-96 ASO
  • the expression of the reporter gene luciferase in the miR-96 receptor vector was restored to 76% of the control level, that is, miR-96 ASO was able to inhibit 54% of miR-96 function.
  • This example is to illustrate the role of miR-96 antisense oligonucleotides in regulating miR-96 target genes and their subsequent effects on energy metabolism in vivo.
  • mice were anesthetized, blood was taken from the right atrium, and the weight of the epididymal fat, stomach, liver, and kidney was dissected and weighed. The results are shown in Figure 4A, and the relative body weight ratio is shown in Figure 4B.
  • Figure 4C Serum was taken after centrifugation at 5000 rpm for 15 minutes, and serum total cholesterol (CHOL), triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were measured using a fully automated biochemical analyzer (Hitachi 7180). The content is shown in Figure 4D.
  • CHOL serum total cholesterol
  • TG triglyceride
  • HDL high density lipoprotein
  • LDL low density lipoprotein
  • miR-96 ASO miR-96 antisense oligonucleotide
  • A body weight
  • B body weight growth rate
  • C hyperglycemia
  • the total RNA of the hypothalamus and stomach of the control and miR-96 ASO-injected mice was extracted according to the method of Example 1, and sequenced and analyzed by the second generation: the miR-96 ASO injection group was up-regulated compared with the control group.
  • Many genes in the MAPK signaling pathway, Wnt signaling pathway, and Hedgehog signaling pathway that inhibit adipocyte differentiation and proliferation, and increase many genes in the insulin signaling pathway and diabetes signaling pathway, as well as in the Jak-STAT signaling pathway regulating appetite Many genes; additionally regulate some of the genes in the signaling pathways regulated by sugar, lipid, and glycolipid metabolism (Table 3).
  • inhibition of miR-96 function can reduce weight gain.
  • the best way to treat severe obesity and diabetes is to perform gastric bypass surgery, which means that the gastrointestinal tract is an important target organ for the treatment of obesity and diabetes.
  • the application demonstrates that inhibition of miR-96 function reduces the weight of stomach and abdominal fat and their ratio to body weight, thus demonstrating that miR-96 is an important target for the treatment of obesity.
  • Inhibition of miR-96 function can reduce hyperglycemia, thus demonstrating that miR-96 is an important target for the treatment of diabetes.
  • the molecular experiments of the present invention demonstrate that miR-96 regulates many genes in the appetite, energy metabolism, fat metabolism and adipocyte differentiation signaling pathways in vivo, which clarifies that miR-96 antisense nucleotides can lower blood fat and lower blood lipids.
  • siRNA small interfering RNA
  • miR-96 siRNA could down-regulate the expression of miR-96 by 70%, and thus the amount of miR-96 bound to the target gene of miR-96 was also down-regulated by 70%, thereby increasing the expression level of the target gene. . It can be seen that the function of miR-96 can also be successfully inhibited by RNA interference with the miR-96 precursor.
  • This example is intended to illustrate the antisense oligonucleotide of thio-modified miR-96 orally (thio-miR-96 ASO: A S G S CAAAAATGTGCTAGTGCCA S A S A, modified site: labeled with "s"
  • thio-miR-96 ASO A S G S CAAAAATGTGCTAGTGCCA S A S A, modified site: labeled with "s”
  • Substituting an oxygen atom in the phosphate in the base of the subscript with sulfur can reduce the weight gain, liver weight, blood lipids, blood sugar and fatty liver formation induced by high fat diet.
  • mice 30 8-10 week old SPF grade C57BL/6 mice (Beijing Weitong Lihua Experimental Animal Co., Ltd.), randomly selected from them Ten were selected and fed normal feed (Beijing Keao Xieli Feed Co., Ltd.), and the remaining 20 were fed 60% kal high fat feed (Beijing Huakang Biotechnology Co., Ltd.). After two weeks of feeding, the mice were weighed once a week. Two weeks later, the mouse body weight growth rate was calculated. Four of the 20 high-fat diet-fed mice had the slowest weight gain or 4 of which were deviated from the population. The remaining 16 rats were divided into 2 groups according to their weight growth rate and body weight, with 8 rats in each group.
  • the fasting blood glucose of the mice was measured. Before taking blood, the animals were fasted overnight, and the tail tip was taken for blood.
  • the PJ150021 gavage group significantly reduced the high body weight growth rate induced by high fat diet, as shown in Figure 7A. Compared with the negative control group, PJ150021 can reduce liver weight and liver coefficient, as shown in Figure 7B-C.
  • Data mean ⁇ SD; * P ⁇ 0.05, ** P ⁇ 0.01, *** P ⁇ 0.001.
  • the present invention can sufficiently inhibit miR-96 in a target cell expressing miR-96 by contacting a miR-96 inhibitor (including an antisense oligonucleotide and an interfering RNA) with a target cell expressing miR-96 in vivo or in vitro.
  • a miR-96 inhibitor including an antisense oligonucleotide and an interfering RNA
  • Function antisense oligonucleotide inhibits the binding of miR-96 to its target gene
  • interfering RNA can reduce the expression of miR-96, thereby inhibiting the function of miR-96
  • the disease caused by an increase in the amount of miR-96 is prevented and/or treated, for example, hyperlipidemia, fatty liver, obesity, and/or diabetes.
  • the present invention Compared with the traditional single hypoglycemic or single hypolipidemic or single weight loss drugs, the present invention provides a comprehensive treatment for appetite, glycolipid metabolism and adipocyte differentiation, and thus has powerful effects and small side effects. It provides a new direction for the treatment of diseases such as obesity, diabetes, fatty liver and hyperlipidemia, and thus has extremely high social and economic benefits.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une utilisation pour la prévention et/ou le traitement, par inhibition d'une fonction miR-96, de l'hyperlipidémie, de la stéatose hépatique, de l'obésité, du diabète et des symptômes similaires aux symptômes de ces maladies. L'invention concerne également un procédé d'inhibition de la fonction miR-96, comprenant une étape consistant à permettre à un inhibiteur de miR-96, tel qu'un oligonucléotide anti-sens, d'entrer en contact avec une cellule cible exprimant miR-96. L'invention concerne également un inhibiteur qui inhibe la fonction miR-96, une composition pharmaceutique ainsi qu'un kit comprenant l'inhibiteur, et son utilisation pour la prévention et/ou le traitement de l'hyperlipidémie, de la stéatose hépatique, de l'obésité, du diabète et des symptômes similaires aux symptômes de ces maladies.
PCT/CN2016/084710 2015-06-05 2016-06-03 Procédé et médicament pour la perte de poids et pour la diminution de la glycémie et de la lipidémie par l'intermédiaire de mir-96, et utilisation associée WO2016192669A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510300150.9 2015-06-05
CN201510300150.9A CN106267207A (zh) 2015-06-05 2015-06-05 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用

Publications (1)

Publication Number Publication Date
WO2016192669A1 true WO2016192669A1 (fr) 2016-12-08

Family

ID=57440188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/084710 WO2016192669A1 (fr) 2015-06-05 2016-06-03 Procédé et médicament pour la perte de poids et pour la diminution de la glycémie et de la lipidémie par l'intermédiaire de mir-96, et utilisation associée

Country Status (2)

Country Link
CN (1) CN106267207A (fr)
WO (1) WO2016192669A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261546A (zh) * 2016-12-29 2018-07-10 昆山彭济凯丰生物科技有限公司 miR-96用于保护肝、肌肉、肺和肾及调控血液总蛋白和白蛋白含量及胰岛素抵抗

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020053186A1 (fr) * 2018-09-11 2020-03-19 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibiteurs de micro-arn a utiliser dans le traitement des maladies métaboliques
CN113288910A (zh) * 2021-05-13 2021-08-24 河北科技师范学院 miR-7a-5p的应用
WO2023143479A1 (fr) * 2022-01-28 2023-08-03 中国医学科学院基础医学研究所 Petit arn et son utilisation dans le traitement de l'hyperlipidémie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013159091A2 (fr) * 2012-04-20 2013-10-24 Aptamir Therapeutics, Inc. Modulateurs de microarn de la thermogenèse
CN103961706A (zh) * 2013-01-30 2014-08-06 中国医学科学院医药生物技术研究所 微小rna或其抑制剂在脂代谢调控中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013159091A2 (fr) * 2012-04-20 2013-10-24 Aptamir Therapeutics, Inc. Modulateurs de microarn de la thermogenèse
CN103961706A (zh) * 2013-01-30 2014-08-06 中国医学科学院医药生物技术研究所 微小rna或其抑制剂在脂代谢调控中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAKRABORTY, C. ET AL.: "Influence of miRNA in Insulin Signaling Pathway and Insulin Resistance: Micro-molecules with a Major Role in Type-2 diabetes", WILEY INTERDISCIPLINARY REVIEWS-RNA, vol. 5, no. 5, 31 October 2014 (2014-10-31), pages 697 - 712, XP055332657, ISSN: 1757-7004 *
LI, WANG ET AL.: "MicroRNAs 185, 96, and 223 Repress Selective High-Density Lipoprotein Cholesterol Uptake through Posttranscriptional Inhibition", MOLECULAR AND CELLULAR BIOLOGY, vol. 33, no. 10, 31 May 2013 (2013-05-31), pages 1956 - 1964, XP055332650, ISSN: 0270-7306 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261546A (zh) * 2016-12-29 2018-07-10 昆山彭济凯丰生物科技有限公司 miR-96用于保护肝、肌肉、肺和肾及调控血液总蛋白和白蛋白含量及胰岛素抵抗

Also Published As

Publication number Publication date
CN106267207A (zh) 2017-01-04

Similar Documents

Publication Publication Date Title
KR101697482B1 (ko) 진단 및 치료 목적을 위한 마이크로ｒｎａ 및 다운스트림 타겟
EP3063276B1 (fr) Micro-arn modulant l'effet de la signalisation des glucocorticoïdes
JP2015518485A (ja) 熱発生のｍｉＲＮＡ調節剤
WO2016192669A1 (fr) Procédé et médicament pour la perte de poids et pour la diminution de la glycémie et de la lipidémie par l'intermédiaire de mir-96, et utilisation associée
CA2801342A1 (fr) Regulation du metabolisme par mir-378
US20120059159A1 (en) Differentiation therapy for sarcomas
WO2018210259A1 (fr) Médicament permettant de réguler l'appétit et le poids corporel, et application associée
WO2017084610A1 (fr) Application de mir-183 ou d'un inhibiteur de celui-ci
EP2852669A1 (fr) Cibles thérapeutiques micro arn dans des maladies pulmonaires chroniques
US8247389B2 (en) Treatment of scleroderma
CN108245527B (zh) 通过miR-1181进行抗癌的方法和药物及其应用
WO2021009363A1 (fr) Utilisations médicales, méthodes et utilisations
CN106581676B (zh) 癌症标志物、治疗癌症的药物组分及用途
WO2018121743A1 (fr) Mir-96 pour protéger le foie, les muscles, les poumons et les reins, pour réguler la teneur en protéine totale et la teneur en albumine dans le sang, et pour la résistance à l'insuline
Luo et al. Nuclear miR-150 enhances hepatic lipid accumulation by targeting RNA transcripts overlapping the PLIN2 promoter
CN114788865B (zh) miR-378作为胆固醇稳态调控靶点的应用
KR102399851B1 (ko) 인슐린 저항성 검출 및 치료용 조성물 및 방법
WO2020184700A1 (fr) Complexe d'acide nucléique pour moduler l'expression d'ihh
WO2023192812A2 (fr) Compositions et méthodes de traitement de troubles musculaires par ciblage d'arn non codants codés par h19x
AU2014256406A1 (en) MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
KR101414383B1 (ko) Ｄｌｋ-1 유전자 발현억제용 조성물
WO2022026648A1 (fr) Inhibition de l'incexact1 pour traiter une maladie cardiaque
JP2010163391A (ja) 糖尿病又は高脂血症治療用医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16802592

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16802592

Country of ref document: EP

Kind code of ref document: A1